![Timothy Kelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 106 763 $ in data 31/07/2026
Timothy P.
Kelly is currently Chief Technology Officer at Caribou Biosciences, Inc. since 2024.
Formerly, Mr. Kelly was Chairman & Chief Executive Officer at Oxford Biomedica Solutions LLC from 2022 to 2023; Chief Operating Officer at Homology Medicines, Inc. from 2021 to 2022; Head-Technical Operations at Sarepta Therapeutics, Inc. in 2017; Senior Vice President & Head-Biologics Operating at Shire Plc from 2016 to 2017; Head-Technical Operations at UCB SA from 2005 to 2009; Senior Director-International Operations at Biogen, Inc. from 1998 to 2005.
Education includes undergraduate studies at the United States Air Force Academy and an MBA from Troy University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 25/02/2026 | 73.125 ( 0,07% ) | 106 763 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 07/01/2024 |
| Società | Posizione | Fine |
|---|---|---|
Oxford Biomedica Solutions LLC
 Oxford Biomedica Solutions LLC Industrial MachineryProducer Manufacturing Operates as an AAV focused manufacturing and innovation company | Amministratore Delegato | 01/07/2023 |
| Q32 BIO INC. | Direttore operativo | 10/03/2022 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2017 |
| SHIRE | Corporate Officer/Principal | 01/01/2017 |
| UCB | Corporate Officer/Principal | 01/01/2009 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
United States Air Force Academy
 United States Air Force Academy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Troy University
 Troy University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage genetic medicines company | Health Technology |
Oxford Biomedica Solutions LLC
Oxford Biomedica Solutions LLC Industrial MachineryProducer Manufacturing Operates as an AAV focused manufacturing and innovation company | Producer Manufacturing |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
